• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

替格瑞洛通过直接改变血小板质膜脂质排列来增加其在 P2Y 受体上的效力。

Ticagrelor increases its own potency at the P2Y receptor by directly changing the plasma membrane lipid order in platelets.

机构信息

Department of Neurochemistry, Palladin Institute of Biochemistry of the NAS of Ukraine, Kyiv, Ukraine.

Department of Physics of Biological Systems, Institute of Physics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine.

出版信息

Br J Pharmacol. 2024 Nov;181(21):4369-4380. doi: 10.1111/bph.16500. Epub 2024 Jul 16.

DOI:10.1111/bph.16500
PMID:39014887
Abstract

BACKGROUND AND PURPOSE

Although the amphiphilic nature of the widely used antithrombotic drug Ticagrelor is well known, it was never considered as a membranotropic agent capable of interacting with the lipid bilayer in a receptor-independent way. In this study, we investigated the influence of Ticagrelor on plasma membrane lipid order in platelets and if this modulates the potency of Ticagrelor at the P2Y receptor.

EXPERIMENTAL APPROACH

We combined fluorescent in situ, in vitro and in silico approaches to probe the interactions between the plasma membrane of platelets and Ticagrelor. The influence of Ticagrelor on the lipid order of the platelet plasma membrane and large unilamellar vesicles was studied using the advanced fluorescent probe NR12S. Furthermore, the properties of model lipid bilayers in the presence of Ticagrelor were characterized by molecular dynamics simulations. Finally, the influence of an increased lipid order on the dose-response of platelets to Ticagrelor was studied.

KEY RESULTS

Ticagrelor incorporates spontaneously into lipid bilayers and affects the lipid order of the membranes of model vesicles and isolated platelets, in a nontrivial composition and concentration-dependent manner. We showed that higher plasma membrane lipid order in platelets leads to a lower IC value for Ticagrelor. It is shown that membrane incorporation of Ticagrelor increases its potency at the P2Y receptor, by increasing the order of the platelet plasma membrane.

CONCLUSION AND IMPLICATIONS

A novel dual mechanism of Ticagrelor action is suggested that combines direct binding to P2Y receptor with simultaneous modulation of receptor-lipid microenvironment.

摘要

背景与目的

尽管广泛使用的抗血栓药物替格瑞洛具有两亲性,但从未被认为是一种能够以非受体依赖的方式与脂质双层相互作用的膜转导剂。在这项研究中,我们研究了替格瑞洛对血小板质膜脂序的影响,以及这种变化是否会调节替格瑞洛在 P2Y 受体上的效力。

实验方法

我们结合荧光原位、体外和计算方法来探测血小板质膜与替格瑞洛之间的相互作用。使用先进的荧光探针 NR12S 研究了替格瑞洛对血小板质膜和大单室囊泡脂序的影响。此外,通过分子动力学模拟研究了替格瑞洛存在下模型脂质双层的性质。最后,研究了增加质膜脂序对血小板对替格瑞洛剂量反应的影响。

主要结果

替格瑞洛自发地掺入脂质双层中,并以非平凡的组成和浓度依赖性方式影响模型囊泡和分离血小板的膜脂序。我们表明,血小板质膜的脂序增加会导致替格瑞洛的 IC 值降低。研究表明,替格瑞洛在质膜中的掺入通过增加血小板质膜的有序性,增加了其在 P2Y 受体上的效力。

结论与意义

提出了替格瑞洛作用的一种新的双重机制,它结合了与 P2Y 受体的直接结合与同时调节受体-脂质微环境。

相似文献

1
Ticagrelor increases its own potency at the P2Y receptor by directly changing the plasma membrane lipid order in platelets.替格瑞洛通过直接改变血小板质膜脂质排列来增加其在 P2Y 受体上的效力。
Br J Pharmacol. 2024 Nov;181(21):4369-4380. doi: 10.1111/bph.16500. Epub 2024 Jul 16.
2
Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane.替格瑞洛对血小板质膜 P2Y1 和 P2Y12 定位及胆固醇水平的影响。
Platelets. 2018 Nov;29(7):709-715. doi: 10.1080/09537104.2017.1356453. Epub 2017 Oct 11.
3
P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.P2Y12 拮抗剂替卡格雷抑制激活的血小板释放促凝细胞外囊泡。
Cardiol J. 2019;26(6):782-789. doi: 10.5603/CJ.a2018.0045. Epub 2018 Apr 19.
4
Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.替格瑞洛抑制人类和鼠类乳腺癌中的血小板-肿瘤细胞相互作用和转移。
Clin Exp Metastasis. 2018 Feb;35(1-2):25-35. doi: 10.1007/s10585-018-9874-1. Epub 2018 Jan 11.
5
The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y inhibition.蛋白酶激活受体 4 第 120 位的丙氨酸突变为苏氨酸变异体改变了血小板对低剂量凝血酶和蛋白酶激活受体 4 脱敏的反应性,并且被非竞争性 P2Y 抑制所阻断。
J Thromb Haemost. 2018 Dec;16(12):2501-2514. doi: 10.1111/jth.14318. Epub 2018 Nov 22.
6
Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.替格瑞洛在人血小板 P2Y12 受体上的竞争模式和相互作用部位。
J Thromb Haemost. 2014 Nov;12(11):1898-905. doi: 10.1111/jth.12719. Epub 2014 Sep 29.
7
Influence of Antiplatelet Agents on the Lipid Composition of Platelet Plasma Membrane: A Lipidomics Approach with Ticagrelor and Its Active Metabolite.抗血小板药物对血小板质膜脂类组成的影响:替格瑞洛及其活性代谢物的脂质组学研究
Int J Mol Sci. 2021 Jan 31;22(3):1432. doi: 10.3390/ijms22031432.
8
Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.血小板补充对血小板 P2Y12 抑制的逆转作用:普拉格雷、氯吡格雷和替格瑞洛的离体和体外比较。
J Thromb Haemost. 2018 Jun;16(6):1089-1098. doi: 10.1111/jth.14014. Epub 2018 Apr 23.
9
Ticagrelor inverse agonist activity at the P2Y receptor is non-reversible versus its endogenous agonist adenosine 5´-diphosphate.替格瑞洛对 P2Y 受体的反向激动剂活性与内源性激动剂腺苷 5´-二磷酸相比是非可逆的。
Br J Pharmacol. 2024 Jan;181(1):21-35. doi: 10.1111/bph.16204. Epub 2023 Sep 1.
10
Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.P2Y12基因多态性对健康中国男性受试者血小板活性的影响,但对替格瑞洛的体外抗血小板作用无影响。
Blood Coagul Fibrinolysis. 2015 Dec;26(8):874-81. doi: 10.1097/MBC.0000000000000308.